Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity
© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society..
CONTEXT: Prader-Willi syndrome (PWS) is characterized by lack of appetite control and hyperphagia, leading to obesity. Pharmacological options for weight management are needed.
OBJECTIVE: To determine whether liraglutide treatment for weight management is superior to placebo/no treatment in pediatric individuals with PWS.
METHODS: This was a multicenter, 52-week, placebo-controlled trial with a 16-week double-blinded period. Adolescents (n = 31, aged 12-17 years; Tanner stage 2-5) and children (n = 24, aged 6-11 years; Tanner stage <2) with PWS and obesity were included. Patients were randomized 2:1 to liraglutide 3.0 mg (or maximum-tolerated dose) or placebo for 16 weeks, after which placebo was stopped. Liraglutide was continued for 52 weeks. All patients followed a structured diet and exercise program throughout the trial. The coprimary endpoints were change in body mass index (BMI) standard deviation score (SDS) from baseline to 16 and 52 weeks. Secondary endpoints included other weight-related parameters, hyperphagia, and safety.
RESULTS: Change in BMI SDS from baseline to weeks 16 and 52 was not significantly different between treatments in adolescents (estimated treatment difference: -0.07 at week 16 and -0.14 at week 52) and children (-0.06 and -0.07, respectively). Changes in other weight-related parameters between treatments were not significant. At week 52, hyperphagia total and drive scores were lower in adolescents treated with liraglutide vs no treatment. The most common adverse events with liraglutide were gastrointestinal disorders.
CONCLUSION: Although the coprimary endpoints were not met, changes in hyperphagia total and drive scores in adolescents warrant further studies on liraglutide in this population.
| Errataetall: |
CommentIn: J Clin Endocrinol Metab. 2023 Jan 13;:. - PMID 36638011 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:108 |
|---|---|
| Enthalten in: |
The Journal of clinical endocrinology and metabolism - 108(2022), 1 vom: 17. Dez., Seite 4-12 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Diene, Gwenaëlle [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
839I73S42A |
|---|
| Anmerkungen: |
Date Completed 20.12.2022 Date Revised 01.02.2023 published: Print CommentIn: J Clin Endocrinol Metab. 2023 Jan 13;:. - PMID 36638011 Citation Status MEDLINE |
|---|
| doi: |
10.1210/clinem/dgac549 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34696976X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34696976X | ||
| 003 | DE-627 | ||
| 005 | 20231226032721.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1210/clinem/dgac549 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1156.xml |
| 035 | |a (DE-627)NLM34696976X | ||
| 035 | |a (NLM)36181471 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Diene, Gwenaëlle |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.12.2022 | ||
| 500 | |a Date Revised 01.02.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: J Clin Endocrinol Metab. 2023 Jan 13;:. - PMID 36638011 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. | ||
| 520 | |a CONTEXT: Prader-Willi syndrome (PWS) is characterized by lack of appetite control and hyperphagia, leading to obesity. Pharmacological options for weight management are needed | ||
| 520 | |a OBJECTIVE: To determine whether liraglutide treatment for weight management is superior to placebo/no treatment in pediatric individuals with PWS | ||
| 520 | |a METHODS: This was a multicenter, 52-week, placebo-controlled trial with a 16-week double-blinded period. Adolescents (n = 31, aged 12-17 years; Tanner stage 2-5) and children (n = 24, aged 6-11 years; Tanner stage <2) with PWS and obesity were included. Patients were randomized 2:1 to liraglutide 3.0 mg (or maximum-tolerated dose) or placebo for 16 weeks, after which placebo was stopped. Liraglutide was continued for 52 weeks. All patients followed a structured diet and exercise program throughout the trial. The coprimary endpoints were change in body mass index (BMI) standard deviation score (SDS) from baseline to 16 and 52 weeks. Secondary endpoints included other weight-related parameters, hyperphagia, and safety | ||
| 520 | |a RESULTS: Change in BMI SDS from baseline to weeks 16 and 52 was not significantly different between treatments in adolescents (estimated treatment difference: -0.07 at week 16 and -0.14 at week 52) and children (-0.06 and -0.07, respectively). Changes in other weight-related parameters between treatments were not significant. At week 52, hyperphagia total and drive scores were lower in adolescents treated with liraglutide vs no treatment. The most common adverse events with liraglutide were gastrointestinal disorders | ||
| 520 | |a CONCLUSION: Although the coprimary endpoints were not met, changes in hyperphagia total and drive scores in adolescents warrant further studies on liraglutide in this population | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a BMI SDS | |
| 650 | 4 | |a Prader–Willi Syndrome | |
| 650 | 4 | |a adolescents | |
| 650 | 4 | |a children | |
| 650 | 4 | |a obesity | |
| 650 | 4 | |a pediatric population | |
| 650 | 7 | |a Liraglutide |2 NLM | |
| 650 | 7 | |a 839I73S42A |2 NLM | |
| 700 | 1 | |a Angulo, Moris |e verfasserin |4 aut | |
| 700 | 1 | |a Hale, Paula M |e verfasserin |4 aut | |
| 700 | 1 | |a Jepsen, Cecilie H |e verfasserin |4 aut | |
| 700 | 1 | |a Hofman, Paul L |e verfasserin |4 aut | |
| 700 | 1 | |a Hokken-Koelega, Anita |e verfasserin |4 aut | |
| 700 | 1 | |a Ramesh, Chethana |e verfasserin |4 aut | |
| 700 | 1 | |a Turan, Serap |e verfasserin |4 aut | |
| 700 | 1 | |a Tauber, Maïthé |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of clinical endocrinology and metabolism |d 1945 |g 108(2022), 1 vom: 17. Dez., Seite 4-12 |w (DE-627)NLM00001821X |x 1945-7197 |7 nnns |
| 773 | 1 | 8 | |g volume:108 |g year:2022 |g number:1 |g day:17 |g month:12 |g pages:4-12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1210/clinem/dgac549 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 108 |j 2022 |e 1 |b 17 |c 12 |h 4-12 | ||